Clinical Trials Logo

Clinical Trial Summary

This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy


Clinical Trial Description

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase Ⅱ Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04443244
Study type Interventional
Source Hugel
Contact
Status Completed
Phase Phase 2
Start date May 27, 2020
Completion date July 16, 2021

See also
  Status Clinical Trial Phase
Completed NCT04294251 - Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy Phase 3
Recruiting NCT05964257 - To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy Phase 3
Not yet recruiting NCT03369990 - DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy Phase 2